A bill requiring dietary supplement manufacturers to list their products with the Food and Drug Administration (FDA) prior to market entry has re-surfaced yet again. Just three months after Sen. Dick Durbin introduced the 2026 version of his Dietary Supplement Listing Act, Rep. Maxine Dexter, MD has reintroduced the same bill earlier this month.
Concerns about the legislation
Over the years, Sen. Durbin has introduced versions of this bill – first in 2022, then in 2024; each time it failed to gain traction. Like his 2026 version, Dexter’s bill would require companies to provide the FDA:
- Product name
- Ingredients used
- E-copy of the label
- Allergen statements
- Health and structure/function claims
Missing the mark for consumers
We believe this mandatory product listing bill is nothing more than unnecessary and burdensome legislation that will inhibit consumer choice and cut access to affordable supplements. FDA currently has the enforcement powers it needs to do its job.
Read our full coverage of Sen. Durbin’s Dietary Supplement Listing Act to see what action you can take to preserve access to the health-supporting supplements you want.
